Compare SharkNinja Inc. Ordinary Shares (SN) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SharkNinja Inc. Ordinary Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? SharkNinja Inc. Ordinary Shares trades at $186 (market cap $26.25B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: SharkNinja Inc. Ordinary Shares is far larger — about 3.6× Spyre Therapeutics Inc. Common Stock's market cap, and SharkNinja Inc. Ordinary Shares is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SharkNinja Inc. Ordinary Shares for 3 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SN | SYRE | |
|---|---|---|
Market Cap | $26.25B | $7.35B |
Volume | 1,135,281 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $192.86 | $108.92 |
52-Week Low | $84.57 | $22.18 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $26.38B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SharkNinja (SN) trades at $188.80, down 0.62% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 10.06% net margin, and robust cash flow growth. Recent product launches including new vacuum and kitchen systems highlight ongoing innovation. Analyst sentiment remains overwhelmingly positive with 91% buy ratings and a $202.18 consensus target.
SN presents a compelling growth story with strong profitability and product momentum, though elevated P/E of 38.5 suggests premium valuation. Key risks include consumer spending sensitivity and competitive pressures in home appliances. The stock's proximity to resistance at $192 requires monitoring for breakout confirmation.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SharkNinja Inc. Ordinary Shares
SharkNinja designs and sells small household appliances under the Shark and Ninja brands. Its products include cleaning appliances, kitchen and beverage appliances, food preparation products, and beauty and home-environment devices.
Read more on SN →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
